



**IWK Health**

Research

5850/5980 University Avenue

PO Box 9700, Halifax

Nova Scotia B3K 6R8

Canada

Tel: 902.470.8888

[www.iwk.nshealth.ca](http://www.iwk.nshealth.ca)

May 21, 2021

**RE: World Journal of Gastroenterology Manuscript NO: 64591, Ethical Review/ Approval Requirement**

To Whom It May Concern,

This letter serves to certify that the studies listed below were reviewed and approved by the IWK Health Research Ethics Board (REB) with Dr Anthony Otley as the Principal Investigator. The approval letters for these studies only exist in paper copy and due to ongoing COVID-19 Pandemic restrictions in Nova Scotia, Canada, these cannot be obtained from our long-term storage facility.

**REB File No.: 3899**

**Title of Protocol:** A Multi-Centre, Double-Blind Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in pediatric Subjects with Moderate to Severe Crohn's Disease

**Approval Date:** 16-APR-2007

**End Date:** 30-JUN-2010

**REB File No.: 2631**

**Title of Protocol:** A Randomized, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Anti-TNF $\alpha$  Chimeric Monoclonal Antibody (Infliximab, REMICADE<sup>®</sup>) in Pediatric Subjects with Moderate to Severe Crohn's Disease

**Approval Date:** 26-JAN-2003

**End Date:** 12-APR-2007

**REB File No.: 2163**

**Title of Protocol:** Pediatric IBD Registry (former title: The Pediatric TREAT<sup>™</sup> Registry: A Pediatric Crohn's Therapy, Resource, Evaluation and Assessment Tool Registry)

**Approval Date:** 18-FEB-2001

**End Date:** 16-JAN-2017

Sincerely,

Eleanor Fitzpatrick

Co-Chair, Research Ethics Board